Aug. 3 at 5:47 PM
$TLTFF company is set to submit New Drug Application to FDA and Health Canada within the next 60 days.
- Ruvidar is extremely safe
- Requires only 1 treatment for NMIBC
- Ruvidar has shown world class results for HSV (topical treatment) in very early stage testing.
- Rutherin being studied for GBM, Lung, and other cancers (same as Ruvidar but intravenous)
- Partnership with Ferring Pharma
- Looking at US IPO in Q1-Q2 2027
This is one of the most undervalued biotech companies out there.